Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PERICYAZINE

All products: general benefit

Other products in the same Health Canada class (N05A) — coverage varies; not interchangeable

  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit
  • Cariprazine (Vraylar): general benefit
  • Chlorpromazine (Teva-Chlorpromazine): general benefit, Not a benefit
  • Flupentixol decanoate (Fluanxol Depot): general benefit

18 more in the class list below

Neuleptil · DIN 01926756 · 10mg/mL · oral liquid

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Neuleptil · DIN 01926756 Manufacturer: Searchlight Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2023-01-27 · brand NEULEPTIL · ATC N05AC01 PERICIAZINE · form Drops · route Oral · ingredients PERICIAZINE 10 MG/ML · company Searchlight pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Neuleptil: Formulary list price $0.4450/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13159 · Verify on the e-Formulary ↗ (DIN 01926756)

Source record
DIN 01926756: Neuleptil Raw flags: sec3=Y Item: 281608049; group id 502; item number 1307; lccId None; manufacturer id SLP Source form: O/L; strength: 10mg/mL Recorded listing: General benefit Source prices (unrounded): $0.4450; ministry $0.4450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926756 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13159
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

LURASIDONE HYDROCHLORIDE

· 38 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) · strengths: 20mg, 40mg, 60mg, 80mg, 120mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications NEULEPTIL (Periciazine capsules; Periciazine oral drops) is indicated: • as adjunctive medication in some psychotic patients and; • for the control of residual prevailing hostility, impulsiveness and aggressiveness. 1.1. Pediatrics Pediatrics (≥ 5 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of NEULEPTIL in pediatric patients above 5 years of age has been established; therefore, Health Canada has authorized an indication for pediatric use (see 7.1 Special Populations, Pediatrics). 1.2. Geriatrics Geriatrics (≥ 65 years): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 3 Serious Warnings and Precautions Box and 7.1 Special Populations, Geriatrics). https://pdf.hres.ca/dpd_pm/00081810.PDF PM date: 2025-09-19 Source product: NEULEPTIL; DIN 01926756; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.